Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer

Abroad (travel likely)RecruitingPHASE1, PHASE2

Conditions

Breast Cancer · Breast Cancer Metastatic · Hormone Receptor Positive Tumor · Human Epidermal Growth Factor 2 Negative Carcinoma of Breast · Ovarian Cancer · CCNE1 Amplification · Solid Tumor · Advanced Cancer · Metastatic Cancer

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations
  • Florida Cancer Specialists, Orlando, Florida, United States

    Contact: Study coordinator (Julia Rivera Otero) · Julia.RiveraOtero@Scri.com
    Contact: Principal Investigator (Cesar Perez, MD)
  • Emory Winship Cancer Institute, Atlanta, Georgia, United States

    Contact: Principal Investigator (Kevin M Kalinsky, MD)
  • Georgia Cancer Center at Augusta University, Augusta, Georgia, United States

    Contact: Study coordinator (Donna Wheatley) · dwheatley@augusta.edu
  • Fort Wayne Medical Oncology and Hematology, Fort Wayne, Indiana, United States

    Contact: Study coordinator (Andrea Vasquez) · andrea.vasquez@aoncology.com
    Contact: Principal Investigator (Sunil Babu, MD)
  • Dana-Farber Cancer Institute, Boston, Massachusetts, United States

    Contact: Study coordinator (Meghan Levesque) · meghan_levesque@dfci.harvard.edu
    Contact: Principal Investigator (Antonio Giordano, MD)
  • Karmanos Cancer Institute, Detroit, Michigan, United States

    Contact: Study coordinator (Madeline McGinnis) · mcginnism@karmanos.org · 313-576-9380
  • Roswell Park Cancer Institute, Buffalo, New York, United States

    Contact: Study coordinator (Ask Roswell) · AskRoswell@RoswellPark.org · 800-767-9355
    Contact: Principal Investigator (Sheheryar Kabraji, MD)
  • Levine Cancer Institute (LCI)- Atrium Health, Charlotte, North Carolina, United States

    Contact: Principal Investigator (Antoinette Tan, MD)
  • Duke Cancer Center/ DUMC, Durham, North Carolina, United States

    Contact: Principal Investigator (Carey Anders, MD)
  • Gabrail Cancer Research Center, Canton, Ohio, United States

    Contact: Study coordinator (Carrie Smith, RN) · csmith@gabrailcancercenter.com
    Contact: Principal Investigator (Nashat Gabrail, MD)
  • Next Oncology, Dallas, Texas, United States

    Contact: Study coordinator (Fope Akinwale) · fakinwale@nextoncology.com
    Contact: Principal Investigator (Michael Song, MD)
  • UTSW Medical Center, Dallas, Texas, United States

    Contact: Study coordinator (Isabel Valenciana) · isabel.villobos@utsouthwestern.edu
    Contact: Principal Investigator (David Miller, MD)
  • Oncology Consultants, Houston, Texas, United States

    Contact: Study coordinator (Site PI) · jpeguero@OncologyConsultants.com · 713-600-0913
    Contact: Principal Investigator (Julio Peguero, MD)
  • Next Oncology, Houston, Texas, United States

    Contact: Study coordinator (Fope Akinwale) · fakinwale@nextoncology.com
    Contact: Principal Investigator (Jennifer Segar, MD)
  • Northwest Medical Specialties, PLLC, Tacoma, Washington, United States

    Contact: Study coordinator (Sue Quinsey) · squinsey@nwmsonline.com · 253-428-8700
    Contact: Principal Investigator (Jorge Chaves, MD)
  • Peninsula and South Eastern Haematology & Oncology Group, Frankston, Victoria, Australia

    Contact: Study coordinator (Albert Goikhman) · ag@paso.com.au
    Contact: Principal Investigator (Vinod Ganju, MD)
  • Peter MacCallum Cancer Center, Parkville, Victoria, Australia

    Contact: Study coordinator (Kim Nayeon) · Nayeon.Kim@petermac.org
    Contact: Principal Investigator (George Au-Yeung, MD)
  • Mater Hospital, South Brisbane, Australia

    Contact: Principal Investigator (Catherine Shannon, MD)